Security Snapshot

CVS HEALTH Corp - Common Stock (CVS) Institutional Ownership

CUSIP: 126650100

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

1,467

Shares (Excl. Options)

640.09MFull value: 640,086,017 · shares · 30 Sep 2026

Price

$85.69

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
CVS on NYSE
All holders as of 30 Sep 2026
Q3 2026
Total 13F shares
640,086,017
Latest holder snapshot 5 signals
Total 13F value
$54,804,920,016
Portfolio coverage rank
0.03%
Share change
+15,233,006
Value change
+$1,324,410,328
Number of holders
1,467
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
1,282,378,590
SEC-reported price per share
$85.69
Insider filing price
$85.69
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • CVS - CVS HEALTH Corp - Common Stock is tracked under CUSIP 126650100.
  • 1467 institutions reported positions in Q3 2026.
  • 4 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 2,077 to 1,467 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $117.54BFull value: $117,544,922,449 · USD · 30 Jun 2026
    to
    $54.8BFull value: $54,804,920,016 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 1467 institutions filings for Q3 2026.

Open SEC evidence

Security key

126650100

13F reference period

Q3 2026

13F holders

1,467

13D/G owners

4

CIK / CUSIP context first

Open Q3 2026 holders CVS full holder history CVS HEALTH Corp SEC filings CVS HEALTH Corp company facts CVS HEALTH Corp insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
4
Security
CVS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 8.3% +17% $7,263,082,720 +$1,108,806,594 105,292,588 +18% BlackRock, Inc. 30 Jun 2025
VANGUARD CAPITAL MANAGEMENT LLC 7.5% $6,865,886,281 95,598,528 Vanguard Capital Management 31 Mar 2026
Capital World Investors 5.5% $4,534,372,461 68,785,990 Capital World Investors 31 Mar 2025
DODGE & COX 3.9% $5,296,351,814 50,012,765 Dodge & Cox 30 Jun 2026
As of 30 Sep 2026, 1,467 institutional investors reported holding
640.09MFull value: 640,086,017 · shares · 30 Sep 2026
shares of CVS HEALTH Corp - Common Stock (CVS). This represents 50% of the company’s total
1.28BFull value: 1,282,378,590 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
39%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD CAPITAL MANAGEMENT LLC 6.5% 83,686,369 +0.45% 0.15% $7,171,084,960
Capital World Investors 5.8% 74,043,290 -1.2% 0.77% $6,345,353,959
STATE STREET CORP 4.7% 60,087,270 -0.33% 0.15% $5,148,878,166
Dodge & Cox 3.6% 46,041,525 -7.9% 2.1% $3,945,298,277
GEODE CAPITAL MANAGEMENT, LLC 2.4% 30,921,045 +3.4% 0.14% $2,638,142,619
VANGUARD PORTFOLIO MANAGEMENT LLC 2.1% 27,110,307 +1.8% 0.1% $2,323,082,207
Capital Research Global Investors 1.7% 21,853,140 -10% 0.27% $1,872,682,211
Invesco Ltd. 1.7% 21,620,892 +5% 0.15% $1,852,694,250
MORGAN STANLEY 1.4% 18,202,910 -2.2% 0.08% $1,559,807,618
Capital International Investors 1.2% 14,882,412 -3.3% 0.26% $1,275,498,963
Davis Selected Advisers 0.93% 11,896,069 +0.25% 4.4% $1,019,375,204
PZENA INVESTMENT MANAGEMENT LLC 0.8% 10,296,903 -13% 2.6% $882,341,618
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 0.75% 9,633,181 +90% 0.35% $825,467,280
Clearbridge Investments, LLC 0.64% 8,188,869 -4.1% 0.61% $701,704,185
Amundi 0.62% 7,930,865 +5.4% 0.15% $679,596,327
DIMENSIONAL FUND ADVISORS LP 0.59% 7,526,125 +2% 0.12% $645,022,466
WCM INVESTMENT MANAGEMENT, LLC 0.57% 7,303,377 1.1% $636,124,137
VANGUARD FIDUCIARY TRUST CO 0.56% 7,220,776 +0.78% 0.13% $618,748,295
FRANKLIN TEMPLETON INC 0.5% 6,381,785 -36% 0.11% $510,296,873
DEUTSCHE BANK AG\ 0.39% 5,022,614 +11% 0.12% $430,387,794
RAYMOND JAMES FINANCIAL INC 0.31% 3,968,614 -8.7% 0.09% $340,070,625
Assenagon Asset Management S.A. 0.3% 3,812,575 +115% 0.33% $326,699,552
Swiss National Bank 0.27% 3,489,860 -2.7% 0.16% $299,046,103
National Pension Service 0.27% 3,425,563 +0.63% 0.18% $293,536,493
Mitsubishi UFJ Asset Management Co., Ltd. 0.26% 3,314,345 +6.3% 0.15% $284,005,805

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 640,086,017 $54,804,920,016 +$1,324,410,328 $85.69 1,467
2026 Q2 1,138,118,678 $117,544,922,449 +$3,347,560,027 $103.45 2,077
2026 Q1 1,105,454,229 $79,351,833,116 -$1,996,383,098 $71.82 1,878
2025 Q4 1,131,876,240 $89,794,715,441 +$2,671,919,542 $79.36 1,938
2025 Q3 1,092,478,965 $82,350,164,002 +$83,483,263 $75.39 1,822
2025 Q2 1,095,036,129 $75,500,979,208 +$2,280,399,011 $68.98 1,740
2025 Q1 1,064,718,943 $72,113,884,722 +$1,899,695,324 $67.75 1,731
2024 Q4 1,045,708,735 $46,960,631,407 +$1,004,418,915 $44.89 1,641
2024 Q3 1,014,230,760 $63,831,005,436 -$677,262,119 $62.88 1,823
2024 Q2 1,019,162,974 $60,179,918,934 +$1,060,433,822 $59.06 1,883
2024 Q1 1,001,904,386 $79,807,139,670 -$1,211,883,033 $79.76 2,137
2023 Q4 1,017,403,858 $80,308,314,517 +$1,281,500,162 $78.96 2,241
2023 Q3 999,658,654 $69,795,638,867 +$491,519,511 $69.82 2,096
2023 Q2 994,552,446 $68,776,049,773 -$267,426,998 $69.13 2,184
2023 Q1 992,137,419 $73,734,702,204 -$2,430,332,032 $74.31 2,238
2022 Q4 1,027,396,077 $95,710,385,316 -$621,742,148 $93.19 2,386
2022 Q3 1,036,131,117 $98,902,299,567 +$583,699,164 $95.37 2,306
2022 Q2 1,030,185,027 $95,477,208,943 +$457,242,938 $92.66 2,292
2022 Q1 1,028,623,372 $104,166,953,205 -$162,318,215 $101.21 2,350
2021 Q4 1,029,470,276 $106,176,980,983 +$782,593,506 $103.16 2,319
2021 Q3 1,017,132,506 $86,349,876,202 +$21,706,246 $84.86 2,053
2021 Q2 1,017,877,459 $84,919,694,336 +$2,053,435,851 $83.44 2,049
2021 Q1 994,144,506 $74,776,454,186 +$4,878,883 $75.23 2,012
2020 Q4 994,787,112 $67,960,797,654 +$33,414,095 $68.30 1,957
2020 Q3 995,752,919 $58,121,993,856 -$1,243,175,311 $58.40 1,799
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .